Sickle cell disease (SCD) is a severe genetic blood disorder characterized by hemolytic
anemia, episodic vaso-occlusion, and progressive organ damage. Current management of …

For over 100 years, clinicians and scientists have been unravelling the consequences of the
A to T substitution in the β-globin gene that produces haemoglobin S, which leads to the …

Abstract Despite Food and Drug Administration (FDA) approval of hydroxyurea to reduce the
frequency of vaso-occlusive episodes, sickle cell disease (SCD) has continued to be treated …

Sickle cell disease afflicts millions of people worldwide and approximately 100,000
Americans. Complications are myriad and arise as a result of complex pathological …

In patients with sickle cell disease (SCD), the polymerization of intraerythrocytic hemoglobin
S promotes downstream vaso-occlusive events in the microvasculature. While vaso …

Individuals with sickle cell disease (SCD) are living further into adulthood in high-resource
countries. However, despite increased quantity of life, recurrent, acute painful episodes …

Sickle cell disease (SCD) afflicts millions of people worldwide and is associated with
considerable morbidity and mortality. Chronic and acute vaso-occlusion are the clinical …

ABSTRACT Introduction: Sickle Cell Disease (SCD) affects 100,000 Americans and more
than 14 million people globally, mostly in economically disadvantaged populations, and …

Sickle cell disease (SCD), considered the most common monogenic disease worldwide, is a
severe hemoglobin disorder. Although the genetic and molecular bases have long been …

Sickle cell disease (SCD) is one of the most common hereditary hemoglobinopathies
worldwide, affecting almost 400,000 newborns globally each year. It is characterized by …